| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e1cf2b6a05b2813470de8b31197ca7d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 |
| filingDate |
2014-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e51a51030e0a7302fe1330c97d80d61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5670081691d0ec10b1d03e769ef760d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5e16a767e272a6d8151b03230a34a29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f896fb7b4dde8bfce3547a6034249718
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32eba1a2aff2d283bbaac239d49ac909
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d11a7a7a90c6a4d76f3e9b5402721d37 |
| publicationDate |
2018-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10017555-B2 |
| titleOfInvention |
Long-acting blood sugar decreasing fusion protein |
| abstract |
The present invention provides an anthropogenic glucagon-like peptide-1 (GLP-1) recombinant protein molecule fused with an anthropogenic immunoglobulin subtype (IgG2) Fc section and a preparation method and purpose thereof. The fusion protein has the biological activity of GLP-1, and also has a significantly prolonged half-life in vivo. The fusion protein can be used to treat type II diabetes, obesity, and other diseases that are treated by decreasing serum glucose, suppressing gastrointestinal motility, and emptying or suppressing food intake. |
| priorityDate |
2013-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |